Citi raises target for Fleury stock from BRL 16 to BRL 23

Published on 10/14/2026 at 02:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit BRL 2.32 billion in the second quarter, up 14.44 percent. Citi estimates BRL 667 million for Fleury stock on November 5, 2026.

Earnings outlook gains weight

Citi lifted its Fleury target from BRL 16 to BRL 23 on October 6, 2026.
Second-quarter revenue reached BRL 2.32 billion, up 14.44 percent year over year.
Fleury is scheduled to report third-quarter results on November 5, 2026.

Fleury, BRFLRYACNOR5, Illustration mit AI erstellt.

Fleury (ISIN BRFLRYACNOR5) is heading into its next results release after Citi raised its price target from BRL 16 to BRL 23 on October 6, 2026, while keeping a neutral rating, according to BP Money. The revision puts earnings expectations and the November reporting date at the center of the stock story.

Three milestones shape the case

Fleury reported BRL 2.32 billion of revenue in the second quarter of 2026, compared with BRL 2.02 billion a year earlier. Net income reached BRL 221.85 million versus BRL 152.30 million, an increase of 45.66 percent, according to Markets Insider.

On October 1, 2026, Fleury announced the acquisition of 100 percent of Unilab for an enterprise value of BRL 55 million. Unilab generated BRL 65 million of gross revenue in the 12 months ended May 2026, and operates 11 diagnostic units, as Exame reported on October 2, 2026.

What does the target change signal?

Citi's target increase came with higher earnings estimates of 11 percent for 2026 and 18 percent for 2027. The same analysis projected third-quarter revenue growth of 12.70 percent year over year and EBITDA of BRL 667 million, while estimating net income at BRL 257 million, 6 percent above market expectations, according to El Fondo.

Results arrive November 5

Fleury is scheduled to report its third-quarter 2026 results on November 5, 2026. Citi expects revenue to rise 12.70 percent year over year, or 10 percent on an organic basis, while recent integration activity could reduce margins by 30 basis points, according to Markets Insider.

Market value sets the scale

Fleury's market capitalization stood at BRL 14.7 billion as of October 13, 2026. The company is listed on B3 under ticker FLRY3 and operates in healthcare, with medical diagnostics as its core business, according to OBM.

Upcoming company dates

The next scheduled reporting date is November 5, 2026, when Fleury is due to publish its third-quarter figures. The combination of BRL 221.85 million in second-quarter net income and the BRL 667 million third-quarter EBITDA estimate gives investors two concrete benchmarks for the next update.